Top Ten Biotechnology Patent Cases of 2024: Loper Bright, Federal Circuit Turmoil, Patent Term Adjustment, and Naturally Occurring Nucleic Acids

Authors

• Kevin E. Noonan, McDonnell Boehnen Hulbert & Berghoff LLPFollow
• Andrew W. Torrance, University of Kansas School of LawFollow

Abstract

A pivotal year for biotechnology patent law, 2024 was marked by consequential court rulings and evolving legal frameworks. This article surveys the ten most significant judicial decisions impacting biotech patents, highlighting major themes and trends in policy, litigation, and regulation. Courts at all levels grappled with core patentability requirements in the life sciences, from the Supreme Court’s continued laissez-faire stance on subject-matter eligibility to the Federal Circuit’s stringent enforcement of disclosure sufficiency rules.

Recommended Citation

Kevin E Noonan & Andrew W. Torrance, Top Ten Biotechnology Patent Cases of 2024: Loper Bright, Federal Circuit Turmoil, Patent Term Adjustment, and Naturally Occurring Nucleic Acids, 28 SMU Sci. & Tech. L. Rev. 579 (2025)